Litcius/Paper detail

First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient

U. Jehn, Ugur Altuner, Hermann Pavenstädt, Stefan Reuter

2022Transplant International12 citationsDOIOpen Access PDF

Abstract

LETTER TO THE EDITOR Transpl Int, 03 October 2022 https://doi.org/10.3389/ti.2022.10846

Topics & Concepts

MedicineEculizumabAtypical hemolytic uremic syndromeRenal transplantThrombotic microangiopathyIntensive care medicineInternal medicineSurgeryKidneyImmunologyComplement systemImmune systemDiseaseComplement system in diseasesAdenosine and Purinergic SignalingRenal Diseases and Glomerulopathies
First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient | Litcius